Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled ...

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% ...

The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied. We ...

Edwards Lifesciences Corp., Orange County’s most valuable publicly traded medical device maker, reported third quarter sales that signaled its biggest unit might be returning to prior sales growth ...

Since the adoption of transcatheter aortic-valve replacement (TAVR), questions have been raised about its effect on clinical practice in comparison with the effect of surgical aortic-valve replacement ...

Medtronic study puts spotlight on how one of its heart devices can help women Study, published in the New England Journal of Medicine, shows how the Evolut TAVR can help treat women with aortic ...

Irvine-based Edwards Lifesciences Corp. (NYSE: EW) said that it’s encouraged by recent streamlining of rules by the Centers for Medicare and Medicaid Services for the life-changing transcatheter ...

Pictured is WellStar Kennestone Hospital's celebration of the milestone 500th TAVR Procedure. Photo special to the MDJ. On Oct. 3, WellStar Kennestone Hospital’s structural heart and valve program ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Aurora St. Luke’s Medical Center and its team of world ...

A Retrospective audit comparing the neutropenic complications in the Pre-COVID and COVID era from a tertiary care center. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...